All News

2019

September

Media Release / Sep 19, 2019

AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

Read More
Media Release / Sep 18, 2019

Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin

Read More
Media Release / Sep 17, 2019

Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis

Read More
Media Release / Sep 13, 2019

Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis

Read More
Media Release / Sep 13, 2019

New Novartis data show that neuronal and glial filaments, biomarkers of disease activity, have the potential to support decision making in the management of multiple sclerosis (MS) patient

Read More
Media Release / Sep 12, 2019

New Novartis data show Mayzent® can help preserve mobility for longer in patients with secondary progressive multiple sclerosis (SPMS)

Read More
Media Release / Sep 10, 2019

Novartis data at ECTRIMS to highlight innovative approach to reimagining care for people living with multiple sclerosis (MS)

Read More
Media Release / Sep 09, 2019

Novartis data confirm long-term efficacy and safety of Aimovig® for majority of patients with episodic migraine

Read More
Media Release / Sep 06, 2019

Novartis investigational lung cancer therapy capmatinib (INC280) granted FDA Breakthrough Therapy Designation for patients with MET-mutated advanced non-small cell lung cancer

Read More
Media Release / Sep 05, 2019

Novartis study shows migraine support in the workplace can improve employee quality of life

Read More

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More